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284 The Journal of Thoracic and Cardbjective: Obesity trends in the Western world parallel the increased incidence of
denocarcinoma of the esophagus and esophagogastric junction. The implications of
besity on standard outcomes in the management of localized adenocarcinoma,
articularly operative risks, have not been systematically addressed.
ethods: This retrospective analysis of prospectively collected data included 150
onsecutive patients (36 [24%] obese [body mass index  30] and 114 nonobese),
f whom 43 were normal weight (body mass index 20–25) and 71 were overweight
body mass index 25–30). Eighty-one patients underwent multimodal therapy. The
rimary end points were in-hospital mortality and morbidity, and median and
verall survivals.
esults: Thirty of 36 obese patients (84%) had a body mass index from 30 to 35.
ompared with those of the nonobese cohort, obese patients had significantly
ncreased respiratory complications (P  .037), perioperative blood transfusions
P  .021), anastomotic leaks (P  .009), and length of stay (P  .001), but no
ifference in mortality (P  .582) or major respiratory complications (P  .171).
edian and overall survivals were equivalent (P  .348) in both groups.
onclusions: Obesity was associated with increased respiratory complications and
nastomotic leak rates but not with major respiratory complications, mortality, or
urvival. These outcomes suggest that the added risks of obesity on standard
utcomes in esophageal cancer surgery are modest and should not independently
ave a significant impact on risk assessment in esophageal cancer management.
he pattern of esophageal cancer in Europe and North America has changed
dramatically in recent decades, with a marked increase in the incidence of
adenocarcinoma of the esophagus and esophagogastric junction.1 The expla-
ation for this increase is unclear, but several risk factors, including chronic
astroesophageal reflux disease, obesity/diet, and Helicobacter pylori eradication,
re plausibly linked with this emerging trend.1,2 Increasing epidemiologic evidence
trongly links obesity and both the incidence of adenocarcinoma at these sites and
eath from this cancer.3-9
Consequently, the esophageal surgeon today is presented increasingly with the
hallenge of managing obese patients with adenocarcinoma of the esophagus or junc-
ion. The risk of operative mortality is up to 10%, with an approximate 50% risk of
orbidity. Some evidence suggests that these risks may be further increased by neo-
djuvant therapy, particularly combination chemotherapy and radiation therapy.10-12
he management of localized disease has a major impact on quality of life over
everal months.13,14 Studies of the implications of obesity, defined by World Health
rganization criteria15 as a body mass index (BMI) of greater than 30 kg/m2, areherefore important, particularly with regard to risk assessment for esophageal
iovascular Surgery ● November 2007
so
c
g
c
o
r
h
c
e
s
e
v
t
o
o
o
I
b
i
s
l
o
t
p
r
r
o
i
W
l
n
M
W
d
t
i
D
e
t
e
w
m
w
T
s
s
3
H
T
s
s
s
u
a
m
L
e
S
a
a
e
c
a
m
p
1
o
a
f
a
B
m
f
I
w
l
r
t
g
b
h
n
G
o
i
t
p
r
s
o
r
w
q
e
Healy et al General Thoracic Surgery
G
TSurgery. A combination of factors, including the association
f obesity with existing comorbidities and medical compli-
ations, the complexity and duration of anesthesia and sur-
ery, and insulin resistance, hormonal alterations, and
hronic inflammation,16 permit the speculative thesis that
besity may increase the incidence of complications.
The principal risks after esophagectomy relate to respi-
atory complications. Intuitively, obese patients may be at
igher risk, because pulmonary function in obese patients is
haracterized by reductions in functional residual capacity,
xpiratory reserve volume, and alveolar oxygen partial pres-
ure, and an increase in the alveolar–arterial oxygen differ-
nce.17,18 The obese patient may consequently be more
ulnerable to significant hypoxia from common postopera-
ive problems, such as atelectasis. Abnormalities in control
f breathing are also common, obstructive sleep apnea may
ccur in up to 40% of men with morbid obesity, and
bstructive hypoventilation syndrome may also occur.19
ntraoperative or postoperative ventilation may be impaired
y reduced compliance of the lung and chest wall and an
ncrease in airway resistance. Moreover, when ventilator
upport is required postoperatively, weaning may be de-
ayed because of this reduced chest wall compliance, and
bese patients compared with nonobese patients have an up
o a 5-fold increase in oxygen uptake when changing from
ositive pressure ventilation to spontaneous breathing as a
esult of the increased work of breathing.16,17
Notwithstanding theoretic concerns, there is currently no
eported systematic assessment of the relationship between
besity and standard outcomes in the management of local-
zed cancer of the esophagus and esophagogastric junction.
e report the experience of this unit and highlight the
argely equivalent outcomes at this time between obese and
onobese cohorts.
aterials and Methods
e performed a retrospective analysis of a prospectively compiled
atabase of patients with histologically proven adenocarcinoma of
he esophagus or esophagogastric junction who underwent surgery
n St James Hospital, Dublin, between January of 1998 and
ecember of 2005. This study was approved by the hospital’s
thics committee. Severely malnourished patients with a BMI less
han 20 kg/m2 (n  5) and patients who underwent an emergency
sophagectomy were excluded from the analysis. Preoperative
eight and height were used to calculate BMI. The preoperative
edical comorbidities and presenting symptoms were noted, as
Abbreviations and Acronyms
ARDS acute respiratory distress syndrome
BMI  body mass index
TRG  tumor regression gradeell as the reported and actual weight loss at time of diagnosis. w
The Journal of Thoraciche patients’ age, cigarette and alcohol consumption, performance
tatus, initial routine blood results, and pulmonary function test
cores were also noted. Obesity was defined as a BMI greater than
0 kg/m2 per World Health Organization and National Institutes of
ealth Clinical Guidelines on the Identification, Evaluation, and
reatment of Overweight and Obesity in Adults.15,20
All patients had localized disease according to clinical, endo-
copic, and computed tomography assessments. Endoscopic ultra-
ound was not routinely used. Fluorodeoxyglucose–positron emis-
ion tomography scanning has been routinely used since 2004. By
sing computed tomography criteria, the mediastinal, left gastric,
nd celiac lymph nodes were classified as N1 (invaded) if the
aximal transverse diameter of these nodes was larger than 1 cm.
ocalized disease was defined as T1-3, N0-1. All tumors of the
sophagogastric junction were assigned as type I, II, or III, per
iewert and Stein.21 Type I is adenocarcinoma of the distal esoph-
gus, usually arising in specialized intestinal metaplasia; type II is
true adenocarcinoma of the cardia arising immediately at the
sophagogastric junction; and type III is a subcardial gastric car-
inoma infiltrating the esophagogastric junction and distal esoph-
gus from below.
Patients with type I and II tumors were considered for
ultimodal therapy involving a regimen of chemotherapy (cis-
latin and fluorouracil) and radiation therapy (40 – 44 Gy in
5–20 fractions) as previously described.22 The majority (97%)
f patients undergoing an esophagectomy had a thoracotomy as
component of their surgical management, combined with the
ollowing: an abdominal and neck exploration (3-stage) for mid
nd upper-esophageal cancers or cancer arising in long-segment
arrett’s esophagus, an abdominal exploration (2-stage) for
ost lower third and junctional tumors, or a total gastrectomy
or junctional tumors with significant gastric extension (type
II). All intrathoracic and cervical anastomoses were performed
ith interrupted single-layer 3-0 polydioxanone (Ethicon, Dub-
in, Ireland). A 2-field lymphadenectomy (abdominal and tho-
acic) was performed in all transthoracic cases. The length of
he operation, intraoperative blood loss, and blood products
iven were all noted.
Unit protocol states that all patients receive epidural analgesia,
e extubated immediately after surgery, and be managed in a
igh-dependency unit. All patients are fed enterally through a
eedle catheter jejunostomy from 12 hours postoperatively. A
astrografin contrast study is performed routinely on day 8 post-
peratively before initiating oral fluids. Throughout the hospital-
zation and at the 3-month follow-up, a dietitian monitored nutri-
ional intake, complications, and body weight changes.
All complications from surgery to discharge from hospital were
rospectively documented. Respiratory failure was defined as the
equirement for mechanical ventilation more than 24 hours after
urgery. Acute respiratory distress syndrome (ARDS) and multiple
rgan failure were defined per Bone and colleagues,23 sepsis
equired evidence of systemic inflammatory response syndrome
ith microbiological evidence of infection, and pneumonia re-
uired positive sputum cultures or clear clinical and radiographic
vidence of consolidation.
Major respiratory complications for the purpose of this analysis
ere defined as pneumonia, empyema, respiratory failure, and
and Cardiovascular Surgery ● Volume 134, Number 5 1285
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G
TSRDS. Any patient who experienced more than 1 major compli-
ation was only included in the analysis once.
The tumor stage was defined according to the TNM staging
ystem and the American Joint Committee on Cancer classifica-
ion.24 Fat-clearing methods were not used to increase lymph node
ield. The definition of a curative resection was that all visible
umor was removed and that proximal, distal, and circumferential
argins were free of tumor on histologic examination. In patients
ndergoing neoadjuvant therapy, the extent of residual carcinoma
n the esophagectomy specimen was assigned to 1 of 5 tumor
egression grade (TRG) categories per Mandard and colleagues:25
RG1 represents fibrosis within the esophageal wall with no
dentifiable residual cancer cells, pathological complete response;
RG2 represents rare residual cancer cells scattered throughout the
brosis; TRG3 represents an increase in the number of residual
ancer cells, but fibrosis still predominant; TRG4 represents re-
idual cancer cells outgrowing fibrosis; and TRG5 represents a
omplete absence of regression change. A TRG of 1 or 2 is deemed
good response, and a TRG of 3 to 5 is deemed a poor response.
tatistical Methods
tatistical analysis was performed using the Statistical Package for
he Social Sciences Version 11.0 for Windows (SPSS Inc, Chi-
ago, Ill). Analysis of variance was used to identify significant
ifferences between BMI categories. Postoperative complications
ere compared using univariate chi-square tests. The primary
omparison was between obese and nonobese cohorts, but some
omparisons were also made between 3 cohorts: obese, over-
eight, and normal weight. Multinominal logistic regression mod-
ls were used to account for potential confounding factors associ-
ted with postoperative complications. The models included age,
ex, heavy alcohol intake, and current smokers. We obtained
azard ratios and 95% confidence interval levels from the models
or the obese and nonobese groups. Actuarial survival was calcu-
ated from the date of first treatment by the Kaplan–Meier method,
nd comparisons between the groups were made by the log–rank
est.
esults
atient Demographics
uring this period, resection for localized disease with
urative intent (anticipated clear margins, R0) was under-
aken in 150 patients, 81 of whom (54%) had neoadjuvant
hemoradiation therapy before surgery according to the unit
rotocol. Forty-three patients (29%) were of normal weight
BMI 20-25 kg/m2), with a weight range between 50 and 85
g; 70 patients (47%) were overweight (BMI 25-30 kg/m2),
ith a weight range of 80 and 130 kg; and 36 patients (24%)
ere obese (BMI 30 kg/m2), with a weight range between
0 and 130 kg. The median BMI was 27 kg/m2. In the obese
roup, 30 patients (83%) had a BMI between 30 and 35
g/m2 (80–115 kg), 4 patients (11%) had a BMI between 35
nd 40 kg/m2 (101–125 kg), and 2 patients (5%) had a BMI
reater than 40 kg/m2 (131 kg) (Table 1).
The clinical pattern of presentation was similar in both
roups. There was no significant difference between obese 5
286 The Journal of Thoracic and Cardiovascular Surgery ● Novnd nonobese patients in known type 2 diabetes, respiratory
isease, or performance status. The incidence of cardiovas-
ular disease was influenced by BMI; 7 of 43 patients (16%)
ith a BMI between 20 and 25 kg/m2 had a history of
ardiovascular disease, compared with 28 of 70 patients
40%) with a BMI between 25 and 30 kg/m2 and 17 of 36
atients (47%) with a BMI more than 30 kg/m2 (P  .003).
In obese patients, preoperative forced expiratory volume
n 1 second (P  .046) and the forced expiratory volume in
second/forced vital capacity ratio (P  .014) were signif-
cantly inferior compared with those of the nonobese group.
his did not relate to tobacco consumption; the highest
ercentage of current smokers (40%) was in the normal
eight groups compared with the overweight (14%) and
bese (19%) groups (P  .042).
reatment Characteristics
here was no significant difference in esophagogastric junc-
ion classification among the BMI categories. Some 67% of
bese patients received multimodal therapy compared with
ABLE 1. Demographics of obese and nonobese groups
emographic details
Nonobese
(n  114)
Obese
(n  36) P value
ex: male/female 98/16 31/5 .216
ge: median (range), y 62 (37–79) 62 (29–79) .521
ymptoms
Dysphagia
Heartburn 81 (71) 29 (81) .183
Regurgitation 36 (32) 11 (31) .541
Weight loss  10% 39 (34) 12 (33) .546
History of GERD  1 y 34 (33) 4 (13) .059
31 (27) 10 (28) .562
moking and alcohol
Never smoked 41 (36) 7 (20)
Ex-smoker (1 y) 46 (40) 22 (61)
Current smoker 27 (24) 7 (19) .076
Heavy alcohol 20 (18) 9 (25) .352
omorbid disease and
performance status
Cardiovascular 35 (31) 17 (47) .033
Respiratory disease 19 (17) 8 (22) .299
Type II diabetes 9 (8) 2 (6) .258
Karnovsky  90% 108 (96) 34 (95) .367
ECOG: fully active 79 (70) 26 (73) .345
ASA grade I or 2 95 (87) 34 (94) .322
ulmonary function tests
FEV1 3.1 (1–5.5) 2.7 (1.1–4.1) .046
FVC 4.0 (2.0–6.4) 3.8 (1.7–5.9) .297
FEV1/FVC ratio 79 (42–94) 74 (53–89) .014
ERD, Gastroesophageal reflux disease; ECOG, Eastern Cooperative On-
ology Group; ASA, American Surgical Association; FEV1, forced expiratory
olume in 1 second; FVC, forced vital capacity.0% of nonobese patients (P  .018). The majority of
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TSatients in both groups underwent a 2-stage esophagectomy
Table 2).
athologic Analysis
he R0 resection rate was 83% and 84% in the obese and
onobese groups, respectively (P  .198). In patients un-
ergoing multimodal therapy, the complete pathologic re-
ponse rate was 12% in the obese group compared with 21%
n the nonobese group (P  .425), and there were no
ifferences between groups in terms of achieving a major
istomorphologic response (TRG1 or 2) at the primary site,
bserved in 42% and 45% in the obese and nonobese
roups, respectively (P  .495). In this cohort, nonobese
atients had more advanced cancer according to pathologic
tage, with 46% of patients presenting with stage 3 disease
ersus 25% of obese patients (P  .013). There was no
ignificant difference in nodal status; the majority of pa-
ients were node-positive: 53% in the obese group versus
1% in the nonobese group (P  .082). The median nodal
ield was significantly (P  .008) greater in the nonobese
roup at 15 (5–46), compared with 10 (4–28) in the obese
atient. Nonobese patients had a significantly greater num-
ABLE 2. Tumor type, treatment details, and pathology
Nonobese
(n  114)
Obese
(n  36) P value
umor location
ower:
ype 1 53 (47) 11 (31) .290
Type 2 42 (38) 21 (60)
Type 3 17 (15) 3 (9)
id 2 (2) 0
ssociated Barrett’s 50 (44) 20 (56) .180
ype of surgery
2-stage esophagectomy 96 (84) 33 (92) .486
3-stage esophagectomy 14 (12) 1 (3)
Transhiatal 3 (3) 1 (3)
Thoracoabdominal 2 (2) 1 (3)
ultimodal therapy 57 (50) 24 (67) .018
athology
Stage 0/1 22 (19) 11 (31)
Stage 2 39 (34) 16 (44)
Stage 3 52 (46) 9 (25) .013
Node positive 70 (61) 20 (53) .082
R0 93 (84) 29 (83) .257
o. of nodes analyzed 15 (5–46) 10 (4–28) .008
esponse to neoadjuvant
therapy (n  81)
TRG 1 and 2 26 (45) 10 (42) .495
TRG 3, 4, and 5 31 (55) 14 (58)
Pathologic complete
response
12 (21) 3 (12) .425
RG, Tumor regression grade.er of positive nodes than obese patients: 3 (0–25) versus 1 t
The Journal of Thoracic0–8) (P  .037). Barrett’s epithelium was present in 56%
f resected specimens in the obese group and 44% in the
onobese group (P  .180).
urgery and In-hospital Complications
here was no significant difference (P  .150) between the
ean duration of surgery in the obese group (350 minutes)
nd nonobese group (320 minutes). The use of blood prod-
cts intraoperatively and in the first 48 hours after surgery in
he obese group (P  .021) was increased, with 24% of
atients requiring over 2 units of blood compared with 7%
n the nonobese group (Table 3).
In-hospital mortality was 6% in both groups. Twenty-one
f 36 obese patients (58%) had a respiratory complication,
ompared with 43 of 114 nonobese patients (38%) (P 
037); however, there was no significant difference between
bese and nonobese groups in major respiratory complica-
ions, including pneumonia (P  .502), ARDS (P  .630),
nd respiratory failure (P  .299). There were 2 cases of
mpyema, both in the obese group (P  .057). An anasto-
otic leak (3 radiologic and 2 clinical) developed in 5
atients in the obese group, compared with 1 clinical and 1
adiologic leak in the nonobese group (P  .009). All were
anaged nonoperatively, and 1 clinical leak in both groups
as managed with endoprosthesis. There were no signifi-
ant differences between groups with respect to venous
ABLE 3. In-hospital postoperative morbidity and mortality
Nonobese
(n  114)
Obese
(n  36) P value
ortality 7 (6) 2 (6) .582
epsis 12 (11) 5 (14) .386
ll respiratory complications 43 (38) 21 (58) .037
ajor respiratory complication* 21 (19) 10 (28) .171
espiratory failure 12 (11) 2 (6) .299
RDS 7 (6) 2 (6) .630
neumonia 15 (13) 4 (11) .502
mpyema 0 2 (6) .057
leural effusion 27 (24) 15 (42) .032
telectasis 9 (8) 5 (14) .121
hromboembolism 3 (3) 1 (3) .436
ajor wound complications 3 (2) 0 .760
rrhythmia 13 (11) 7 (19) .168
nastomotic leak 2 (2) 5 (14) .009
enal dysfunction 9 (8) 2 (6) .482
lood products†
0 64 (58) 13 (39) .021
1–2 units 38 (34) 12 (36)
2 units 8 (7) 8 (24)
RDS, Acute respiratory distress syndrome. *Number of patients with a
ajor respiratory complication (ie, pneumonia, respiratory failure, ARDS,
r empyema). †Blood products given intraoperatively or within 48 hours
ostoperatively.hromboembolism (P  .436), major wound problems (P 
and Cardiovascular Surgery ● Volume 134, Number 5 1287
..
o
c
(
.
c
2
(
(
l
P
A
j
o
f
1
O
p
2
S
A
(
w
a
t
t
D
O
i
d
t
p
i
g
p
p
e
o
i
a
t
g
c
t
p
c
c
f
a
v
p
a
p
r
t
n
i
t
2
f
a
U
1
T
n
a
a
c
i
c
t
i
i
s
r
t
n
p
T
g
n
w
t
o
l
s
T
p
A
M
c
P
A
O
a
General Thoracic Surgery Healy et al
1
G
TS760), arrhythmias (P  .168), and renal dysfunction (P 
482). The median stay in the high-dependency unit post-
peratively was 4 days (0–14 days) in the obese group
ompared with 4 days (0–32 days) in the nonobese group
P .937). The median hospital stay was significantly (P
001) greater at 23 days (13–94 days) in the obese group
ompared with 18 days (1–61 days) in the nonobese group.
On multivariate analysis (Table 4), obese patients were
.6 times more likely to have any respiratory complication
P  .014), 2.7 times more likely to have a pleural effusion
P .019), and 11 times more likely to have an anastomotic
eak (P  .006) than nonobese patients.
ostoperative Nutrition
ll patients were nutritionally supported via a feeding je-
unostomy in the postoperative period. The median duration
f postoperative nutrition support (full feeding or overnight
eeding) was 16 days (10–80 days) in the obese group and
5 days (2–53 days) in the nonobese group (P  .128).
bese patients lost more weight postoperatively as in-
atients compared with nonobese patients (4.7 [0–26] kg vs
.8 [0–14] kg; P  .048).
urvival
t a median follow-up of 39 months, the median survival
Figure 1) in the obese group was 27 months, compared
ith 25 months in the nonobese group (P  .348). The 1, 3,
nd 5-year survivals were 75%, 46%, and 46%, respec-
ively, in the obese group, and 75%, 34%, and 22%, respec-
ively, in the nonobese group.
iscussion
besity, defined as a BMI greater than 30 kg/m2, has
ncreased in incidence in the developed world in the last
ecade. Approximately 30% of the population are obese in
he United States, and more than 100,000 operations were
erformed for morbid obesity in 2004.26,27 The increased
ncidence of adenocarcinoma of the esophagus and esopha-
ogastric junction in recent decades parallels the increasing
revalence of obesity. In an Irish cohort we recently re-
ABLE 4. Relative hazard ratios for obesity and
ostoperative complication
P value OR 95% CI
ll respiratory complications .014 2.6 1.2–5.9
ajor respiratory .283 2.7 1.1–6.4
omplications
leural effusion .019 2.7 1.1–6.4
nastomotic leak .006 11 2.0–61.7
R, Odds ratio; CI, confidence interval. Adjusted for age, sex, heavy
lcohol intake, and current smokers.orted that 82% of patients with adenocarcinoma of the c
288 The Journal of Thoracic and Cardiovascular Surgery ● Novsophagus or esophagogastric junction were overweight or
bese, and that obesity in males was associated with a 4-fold
ncrease risk of adenocarcinoma.8 The explanation for this
ssociation is unclear. One possible mechanism links the
ypical male central adiposity with chronic gastroesopha-
eal reflux disease, both of which are independently asso-
iated with adenocarcinoma of the esophagus and junc-
ion.28 In addition to a mechanical link, the pleiotropic
roperties of the adipocyte have come under scrutiny, be-
ause adipocytes from central fat may have endocrine, para-
rine, and immunologic properties.29 This may be mani-
ested in the metabolic syndrome, which is a constellation of
therogenic dyslipidemia, elevated blood pressure, and ele-
ated blood glucose associated with insulin resistance. The
roinflammatory response associated with central adiposity
nd the metabolic syndrome may, at least theoretically,
romote inflammation and tumorigenic pathways that are
elevant to esophageal adenocarcinoma and other tumor
ypes.16
Surgery for esophageal cancer is associated with a sig-
ificant risk of morbidity and mortality, and has a major
mpact on quality of life.1 A recent review of 70,000 pa-
ients reported a mortality of 6.7% between 1990 and
000.30 The combined Veterans Administration experience
or the same period reported a major morbidity rate of
pproximately 50% and a mortality rate of 10%.10 In the
nited Kingdom, McCulloch and colleagues31 reported a
2% in-hospital mortality rate from a multicenter series.
he recent advent of multimodality regimens, particularly
eoadjuvant combination chemotherapy and radiation ther-
py, may further increase operative risks.11,12 It is unassail-
ble that there is no common elective cancer surgery that
arries the same risks. In an era of risk stratification and
nformed consent, data on the impact of obesity on out-
omes after esophagectomy are increasingly important, and
o our knowledge this is the first report specifically address-
ng the relationship of obesity to the standard outcome
ndicators of an esophageal unit.
In this study, no increase in in-hospital mortality was ob-
erved in the obese cohort. Respiratory complications were
igorously recorded, and an increased incidence of complica-
ions was observed in the obese cohort. There was, however,
o increase in the more major complications of postoperative
neumonia, respiratory failure, or ARDS in the obese group.
he incidence of anastomotic leaks was increased in the obese
roup; however, the incidence of clinically evident leaks was
ot significantly different. The incidence of anastomotic leak
as low (3%), compared with the reported incidence of up
o 10% post-esophagectomy.32,33 On univariate analysis,
besity was the only factor associated with anastomotic
eak, and there was no relationship to incidence and age,
ex, American Surgical Association grade, smoking, or al-
ohol use. Obesity was associated with the risk of anasto-
ember 2007
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TSotic leak after resection and primary anastomosis for
eft-sided colonic emergencies.34 The factors involved in
he increased leaks observed in the obese group in this study
re unclear, but we speculate that the dependence of touch
nd judgment rather than clear visibility of the right gastro-
piploic vessels, as well as increased tension of the conduit
n the high thorax or the cervical site, may compromise the
ascularity of the gastric anastomotic site. Other factors,
uch as diabetes and cardiovascular disease, may also be
ontributory, but this was not evident in this analysis.
The concern that obese patients would have a higher
ncidence of wound infections and dehiscence could not be
erified, and the incidence of clinical venous thromboem-
olism was low in this study in which all patients received
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Non-Obese
Obese median survival = 29 months 
Non obese median survival = 25 months 
Non-Obese
Survival time No at Risk 
0 year 114
1 year 81
3 years 21
5 years 10
Obese
Survival time No at Risk 
0 year 36
1 year 26
3 years 11
5 years 6
Figurerophylactic low molecular weight heparin. Blood transfu- s
The Journal of Thoracicion requirements were significantly increased in the obese
roup, and obesity was associated with a significantly
onger duration of postoperative hospital stay.
Esophagectomy is associated with significant metabolic,
ndocrine, and immunoinflammatory changes. A similar
pectrum of response is seen after major blunt trauma. In
tudies of patients with blunt trauma, however, and in
ontrast with this study, Smith–Choban and colleagues35
eported a 42% mortality in obese patients versus 7% for
onobese patients, and respiratory failure as the result of
RDS was the primary cause. In a study by Neville and
olleagues36 on 242 patients admitted to the intensive care
nit after blunt trauma, 62 were obese and the odds ratio of
ortality was 5.7 compared with the nonobese cohort. In a
3 4 5
P=0.348
Obese
Deaths % Survival 
0 100%
23 75%
36 34%
7 22%
Deaths % Survival 
0 100%
8 75%
9 46%
0 46%
rvival.Year
1. Sutudy of patients undergoing liver transplantation, obesity
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G
TSas associated with an increased incidence of multiple
rgan failure.37 The lack of major added risks associated
ith obesity in this study is consistent with reports of
quivalent complication rates in obese and nonobese pa-
ients undergoing cardiac surgery, in which the increased
isk of complications seems to be evident only in patients
ith extreme obesity (BMI  40 kg/m2).38 Only 2 patients
n this study had a BMI greater than 40 kg/m2; both patients
ad sleep apnea and 1 patient had obesity hypoventilation
yndrome, but both survived without major complications.
t is clear that risk assessment in the morbidly obese patient
annot be inferred from this study of predominantly patients
ith a BMI from 30 to 35 kg/m2.
Frequent symptoms of reflux are associated with increased
isks of Barrett’s esophagus, and these risks are substantially
levated by obesity and smoking.39 In a population-based
tudy39 in obese patients (BMI  30), the risk of Barrett’s
sophagus was minimal with no reflux symptoms (odds ratio:
.7 95% confidence interval 0.2–2.4) and increased dramati-
ally with weekly reflux symptoms (odds ratio: 34.4 95%
onfidence interval 6.3–188). There was no difference in the
eported incidence of gastroesophageal reflux disease in this
opulation, which may explain the lack of association between
besity and Barrett’s esophagus. This study also addressed the
tandard oncologic indicators, and there was no differences in
O resection rate, tumor response rate, and survival. Nodal
ield was less in the obese cohort, perhaps reflecting the lack
f routine fat-clearing mechanisms by pathologists.
imitations
he limitations of the study are acknowledged, particularly
he retrospective nature of the analysis. Prospective study in
his unit now encompasses assessment of the metabolic
yndrome, comprehensive respiratory physiology analysis
retreatment, documentation on intraoperative and early
ostoperative dynamics in respiratory physiology, and stud-
es of immune function and metabolism in the perioperative
eriod. Underweight patients (BMI  20 kg/m2) were also
xcluded because of the small number (n  5) of the cohort
nd the fact that they represent a high-risk group. When all
atients were included and the population was divided into
uintiles or tertiles, a significant association of the highest
uintile or tertile with anastomotic leaks and respiratory
omplications remained evident (data not shown).
onclusions
his study shows that obese patients undergoing surgical or
ultimodality management of localized adenocarcinoma of
he esophagus or esophagogastric junction have a longer
ospital stay, an increased incidence of respiratory compli-
ations and radiologic anastomotic leaks, and greater re-
uirements for blood products compared with nonobese
atients. There was no difference in mortality or major
290 The Journal of Thoracic and Cardiovascular Surgery ● Novomplications, and the cancer survival outcomes are equiv-
lent. Risk stratification is the ultimate motivation for es-
ablishing complication rates in obese patients undergoing
sophageal surgery, and this study shows that surgery was
ndertaken in an obese population, predominantly patients
ith a BMI between 30 and 35 kg/m2, with no major
ncreased risk of serious morbidity or mortality.
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